← All trials
NCT05651074
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 14, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Jan 31, 2023
- First posted
- Dec 14, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu vcare pharmaceutical technology co., LTDLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.